Efficacy and Safety of Mammalian Target of Rapamycin Inhibitor Use—Long-term Follow-up of First Tuberous Sclerosis Complex Patient Treated De Novo With Sirolimus After Kidney Transplantation: A Case Report-Reference-Cited by-同舟云学术

Efficacy and Safety of Mammalian Target of Rapamycin Inhibitor Use—Long-term Follow-up of First Tuberous Sclerosis Complex Patient Treated De Novo With Sirolimus After Kidney Transplantation: A Case Report

Published:2018-07 Issue:6 Volume:50 Page:1904-1909
ISSN:0041-1345
Container-title:Transplantation Proceedings
language:en
Short-container-title:Transplantation Proceedings

Author:

Tarasewicz A.,Dębska-Ślizień A.,Rutkowska B.,Szurowska E.,Matuszewski M.

Publisher

Elsevier BV

Subject

Transplantation,Surgery

Reference39 articles.

1. Recent advances and challenges of mTOR inhibitors use in the treatment of patients with tuberous sclerosis complex;Palavra;Oxid Med Cell Longev,2017

2. mTOR signaling in growth, metabolism, and disease;Saxton;Cell,2017

3. mTOR signaling in growth control and disease;Laplante;Cell,2012

4. mTORC1 signaling and the metabolic control of cell growth;Ben-Sahra;Curr Opin Cell Biol,2017

5. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling;Tee;Proc Natl Acad Sci U S A,2002

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapamycin protects against aristolochic acid nephropathy in mice by potentiating mammalian target of rapamycin‑mediated autophagy;Molecular Medicine Reports;2021-05-05

2. mTOR-Mediated Cell Death and Infection;Infectious Microbes and Diseases;2021-05-04

3. Living Donor Preemptive Kidney Transplantation in Tuberous Sclerosis Complex Patient and the Role of Mammalian Target of Rapamycin Inhibitor: A Case Report;Transplantation Proceedings;2020-10

4. Methylomic correlates of autophagy activity in cystic fibrosis;Journal of Cystic Fibrosis;2019-07

5. Sirolimus;Reactions Weekly;2018-08